Mitochondrial changes in leukocytes of patients with optic neuritis

Molecular Vision

Volumn 13, Issue , 2007, Pages 1516-1528

  Bosley, Thomas M ^a,b   Constantinescu, Cris S ^c   Tench, Christopher R ^c   Abu Amero, Khaled K ^a,d  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d Shafallah Medical Genetics Center   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GUANOSINE TRIPHOSPHATASE; INTERFERON; MITOCHONDRIAL DNA; OPTIC ATROPHY TYPE 1 PROTEIN; OPTIC ATROPHY TYPE 3 PROTEIN; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLOR VISION; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEBER HEREDITARY OPTIC NEUROPATHY; LEUKOCYTE; MALE; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; NEUROIMAGING; OPTIC NERVE ATROPHY; OPTIC NEURITIS; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

ADOLESCENT; ADULT; COLOR PERCEPTION; DEMYELINATING DISEASES; DNA, MITOCHONDRIAL; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LEUKOCYTES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOCHONDRIA; MULTIPLE SCLEROSIS; OPTIC NEURITIS; OXYGEN CONSUMPTION; PROTEINS; RECOVERY OF FUNCTION; VARIATION (GENETICS); VISUAL ACUITY;

EID: 34548299117     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111-21.
2. Kalman B. Role of mitochondria in multiple sclerosis. Curr Neurol Neurosci Rep 2006; 6:244-52.
3. Newman NJ. Hereditary optic neuropathies: from the mitochondria to the optic nerve. Am J Ophthalmol 2005; 140:517-23.
4. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, Bhattacharya SS, Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26:211-5.
5. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26:207-10.
6. Zuchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas F, Bird T, Timmerman V, Shy M, Vance JM. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 2006; 59:276-81.
7. Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellar-Wood H, Menard D, McDonald WI, Compston DA. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992; 115:979-89.
8. Ebers GC, Sadovnick AD. Susceptibility: Genetics in Multiple Sclerosis. In: Paty DW, Ebers GC, editors. Multiple Sclerosis. Philadelphia: FA Davis Company; 1998. p. 29-47.
9. Kao SH, Chao HT, Liu HW, Liao TL, Wei YH. Sperm mitochondrial DNA depletion in men with asthenospermia. Fertil Steril 2004; 82:66-73.
10. Abu-Amero KK, Bosley TM. Detection of mitochondrial respiratory dysfunction in circulating lymphocytes using resazurin. Arch Pathol Lab Med 2005; 129:1295-8.
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-31.
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-7.
13. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003; 74:1090-4.
14. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, Lechner H. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38:1822-5.
15. Frisard M, Ravussin E. Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process. Endocrine 2006; 29:27-32.
16. Abu-Amero KK, Alzahrani AS, Zou M, Shi Y. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/ multiple endocrine neoplasia type 2 syndrome. Oncogene 2006; 25:677-84.
17. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 1999; 23:147.
18. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, Wallace DC. MITOMAP: a human mitochondrial genome database - 2004 update. Nucleic Acids Res 2005; 33:D611-3.
19. Bandelt HJ, Salas A, Bravi CM. What is a 'novel' mtDNA mutation - and does 'novelty' really matter? J Hum Genet 2006; 51:1073-82.
20. Chinnery PF, Howell N, Andrews RM, Turnbull DM. Mitochondrial DNA analysis: polymorphisms and pathogenicity. J Med Genet 1999; 36:505-10.
21. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001; 10:591-7.
22. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002; 12:436-46.
23. Fahy E, Nazarbaghi R, Zomorrodi M, Herrnstadt C, Parker WD, Davis RE, Ghosh SS. Multiplex fluorescence-based primer extension method for quantitative mutation analysis of mitochondrial DNA and its diagnostic application for Alzheimer's disease. Nucleic Acids Res 1997; 25:3102-9.
24. Wu CW, Yin PH, Hung WY, Li AF, Li SH, Chi CW, Wei YH, Lee HC. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 2005; 44:19-28.
25. Taanman JW, Bodnar AG, Cooper JM, Morris AA, Clayton PT, Leonard JV, Schapira AH. Molecular mechanisms in mitochondrial DNA depletion syndrome. Hum Mol Genet 1997; 6:935-42.
26. Yen MY, Chen CS, Wang AG, Wei YH. Increase of mitochondrial DNA in blood cells of patients with Leber's hereditary optic neuropathy with 11778 mutation. Br J Ophthalmol 2002; 86:1027-30.
27. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47:2533-41.
28. Abu-Amero KK, Bosley TM. Mitochondrial abnormalities in patients with LHON-like optic neuropathies. Invest Ophthalmol Vis Sci 2006; 47:4211-20.
29. Abu-Amero KK, Bosley TM. Increased relative mitochondrial DNA content in leucocytes of patients with NAION. Br J Ophthalmol 2006; 90:823-5.
30. Azbill RD, Mu X, Bruce-Keller AJ, Mattson MP, Springer JE. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Res 1997; 765:283-90.
31. White MJ, DiCaprio MJ, Greenberg DA. Assessment of neuronal viability with Alamar blue in cortical and granule cell cultures. J Neurosci Methods 1996; 70:195-200.
32. Visser W, Scheffers WA, Batenburg-van der Vegte WH, van Dijken JP. Oxygen requirements of yeasts. Appl Environ Microbiol 1990; 56:3785-92.
33. Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, Andreasson S, Van Regemorter N, Munier FL, Moore AT, Bhattacharya SS, Votruba M. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci 2002; 43:1715-24.
34. Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 2001; 69:1218-24.
35. Taylor RW, Taylor GA, Morris CM, Edwardson JM, Turnbull DM. Diagnosis of mitochondrial disease: assessment of mitochondrial DNA heteroplasmy in blood. Biochem Biophys Res Commun 1998; 251:883-7.
36. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673-8.
37. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCray JA, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581-8.
38. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186-92.
39. Delettre C, Lenaers G, Pelloquin L, Belenguer P, Hamel CP. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease. Mol Genet Metab 2002; 75:97-107.
40. Bosley TM, Abu-Amero KK, Ozand PT. Mitochondrial DNA nucleotide changes in non-arteritic ischemic optic neuropathy. Neurology 2004; 63:1305-8.
41. Manfredi G, Schon EA, Moraes CT, Bonilla E, Berry GT, Sladky JT, DiMauro S. A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromuscul Disord 1995; 5:391-8.
42. Votruba M. Molecular genetic basis of primary inherited optic neuropathies. Eye 2004; 18:1126-32.
43. Battisti C, Formichi P, Cardaioli E, Bianchi S, Mangiavacchi P, Tripodi SA, Tosi P, Federico A. Cell response to oxidative stress induced apoptosis in patients with Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2004; 75:1731-6.
44. Roed H, Frederiksen J, Langkilde A, Sorensen TL, Lauritzen M, Sellebjerg F. Systemic T-cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005; 162:165-72.
45. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004; 23:53-89.
46. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11:107-16.
47. Qi X, Lewin AS, Hauswirth WW, Guy J. Suppression of complex I gene expression induces optic neuropathy. Ann Neurol 2003; 53:198-205.
48. Barnett MH, Sutton I. The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 2006; 19:242-7.
49. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59:478-89.
50. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55:458-68.
51. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007; 48:681-91.
52. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007; 58:417-32.
53. Guy J, Qi X, Pallotti F, Schon EA, Manfredi G, Carelli V, Martinuzzi A, Hauswirth WW, Lewin AS. Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol 2002; 52:534-42.
54. Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973; 90:349-54.